David T Woodley

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/528112/david-t-woodley-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69 papers	6,055 citations	40 h-index	74 g-index
74 ext. papers	6,743 ext. citations	7.7 avg, IF	5.13 L-index

#	Paper	IF	Citations
69	Evaluation of Systemic Gentamicin as Translational Readthrough Therapy for a Patient With Epidermolysis Bullosa Simplex With Muscular Dystrophy Owing to PLEC1 Pathogenic Nonsense Variants.. *JAMA Dermatology*, **2022**,	5.1	2
68	Immunoglobulin and Complement Immunohistochemistry on Paraffin Sections in Autoimmune Bullous Diseases: A Systematic Review and Meta-analysis. *American Journal of Dermatopathology*, **2021**, 43, 689-699	0.9	2
67	Association between vaccination and autoimmune bullous diseases: A□ystematic review. *Journal of the American Academy of Dermatology*, **2021**,	4.5	7
66	Over-expression of stromal periostin correlates with poor prognosis of cutaneous squamous cell carcinomas. *Experimental Dermatology*, **2021**, 30, 698-704	4	4
65	Characterization of mutant type VII collagens underlying the inversa subtype of recessive dystrophic epidermolysis bullosa. *Journal of Dermatological Science*, **2021**, 104, 104-111	4.3	0
64	Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic-Consensus: Recommendations by an international panel of experts. *Journal of the American Academy of Dermatology*, **2020**, 83, 1222-1224	4.5	5
63	Gentamicin Induces Laminin 332 and Improves Wound Healing in Junctional Epidermolysis Bullosa Patients with Nonsense Mutations. *Molecular Therapy*, **2020**, 28, 1327-1338	11.7	13
62	Clinical outcomes of patients with pemphigus treated by the same physicians in a public safety net healthcare system vs. a private healthcare system. *British Journal of Dermatology*, **2019**, 181, 850-852	4	
61	Improving Hairdressers' Knowledge and Self-efficacy to Detect Scalp and Neck Melanoma by Use of an Educational Video. *JAMA Dermatology*, **2018**, 154, 214-216	5.1	6
60	Gentamicin induces nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E6536-E6545	11.5	32
59	Distinct Fibroblasts in the Papillary and Reticular Dermis: Implications for Wound Healing. *Dermatologic Clinics*, **2017**, 35, 95-100	4.2	53
58	Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients. *Journal of Clinical Investigation*, **2017**, 127, 3028-3038	15.9	61
57	Keratinocyte Migration and a Hypothetical New Role for Extracellular Heat Shock Protein 90 Alpha in Orchestrating Skin Wound Healing. *Advances in Wound Care*, **2015**, 4, 203-212	4.8	24
56	Intravenously Administered Recombinant Human Type VII Collagen Derived from Chinese Hamster Ovary Cells Reverses the Disease Phenotype in Recessive Dystrophic Epidermolysis Bullosa Mice. *Journal of Investigative Dermatology*, **2015**, 135, 3060-3067	4.3	19
55	Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa. *Journal of Pediatrics*, **2015**, 167, 765-9.e1	3.6	21
54	Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. *Journal of the American Academy of Dermatology*, **2015**, 72, 168-74	4.5	93
53	Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa. *Molecular Therapy*, **2014**, 22, 1741-52	11.7	44

52	Omalizumab therapy for bullous pemphigoid. *Journal of the American Academy of Dermatology*, **2014**, 71, 468-74	4.5	109
51	De novo anti-type VII collagen antibodies in patients with recessive dystrophic epidermolysis bullosa. *Journal of Investigative Dermatology*, **2014**, 134, 1138-1140	4.3	30
50	Identification of the critical therapeutic entity in secreted Hsp90 that promotes wound healing in newly re-standardized healthy and diabetic pig models. *PLoS ONE*, **2014**, 9, e113956	3.7	24
49	Topical application of recombinant type VII collagen incorporates into the dermal-epidermal junction and promotes wound closure. *Molecular Therapy*, **2013**, 21, 1335-44	11.7	44
48	Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen. *Autoimmunity*, **2012**, 45, 91-101	3	49
47	Epidermolysis bullosa acquisita. *Clinics in Dermatology*, **2012**, 30, 60-9	3	119
46	Successful treatment of bullous pemphigoid with omalizumab. *Archives of Dermatology*, **2012**, 148, 1241-3		42
45	Epidermolysis Bullosa Acquisita **2011**, 113-136		
44	Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. *New England Journal of Medicine*, **2010**, 363, 629-39	59.2	262
43	Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. *Molecular Therapy*, **2009**, 17, 26-33	11.7	107
42	TANGO1 facilitates cargo loading at endoplasmic reticulum exit sites. *Cell*, **2009**, 136, 891-902	56.2	254
41	151A Traffic Control Role for TGF-Beta in Skin Cell Motility During Wound Healing. *Wound Repair and Regeneration*, **2008**, 13, A28-A48	3.6	
40	The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. *Journal of the American Academy of Dermatology*, **2008**, 58, 931-50	4.5	690
39	Characterization of molecular mechanisms underlying mutations in dystrophic epidermolysis bullosa using site-directed mutagenesis. *Journal of Biological Chemistry*, **2008**, 283, 17838-45	5.4	26
38	Duplicating autoimmune bullous diseases by passively transferring autoantibodies into animals. *Journal of Investigative Dermatology*, **2008**, 128, E25-7	4.3	1
37	Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. *Molecular Therapy*, **2007**, 15, 628-35	11.7	88
36	Autoimmunity to type VII collagen: epidermolysis bullosa acquisita. *Clinical Reviews in Allergy and Immunology*, **2007**, 33, 78-84	12.3	42
35	The role of IgE anti-basement membrane zone autoantibodies in bullous pemphigoid. *Archives of Dermatology*, **2007**, 143, 249-50		7

34	The cartilage matrix protein subdomain of type VII collagen is pathogenic for epidermolysis bullosa acquisita. *American Journal of Pathology*, **2007**, 170, 2009-18	5.8	53
33	Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. *Journal of Investigative Dermatology*, **2006**, 126, 1323-30	4.3	80
32	Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. *Journal of Investigative Dermatology*, **2005**, 124, 958-64	4.3	88
31	Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. *Nature Medicine*, **2004**, 10, 693-5	50.5	111
30	Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. *Molecular Therapy*, **2004**, 10, 318-26	11.7	70
29	Epidermolysis bullosa: then and now. *Journal of the American Academy of Dermatology*, **2004**, 51, S55-7	4.5	8
28	Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. *Journal of Investigative Dermatology*, **2003**, 121, 1021-8	4.3	93
27	Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. *Nature Genetics*, **2002**, 32, 670-5	36.3	144
26	The recombinant expression of full-length type VII collagen and characterization of molecular mechanisms underlying dystrophic epidermolysis bullosa. *Journal of Biological Chemistry*, **2002**, 277, 2118-24	5.4	59
25	The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. *Archives of Dermatology*, **2002**, 138, 370-9		526
24	The carboxyl terminus of type VII collagen mediates antiparallel dimer formation and constitutes a new antigenic epitope for epidermolysis Bullosa acquisita autoantibodies. *Journal of Biological Chemistry*, **2001**, 276, 21649-55	5.4	58
23	Epidermolysis bullosa acquisita: update and review. *Clinics in Dermatology*, **2001**, 19, 712-8	3	43
22	Autoantibodies to type VII collagen have heterogeneous subclass and light chain compositions and their complement-activating capacities do not correlate with the inflammatory clinical phenotype. *Journal of Clinical Immunology*, **2000**, 20, 416-23	5.7	18
21	NC1 domain of type VII collagen binds to the beta3 chain of laminin 5 via a unique subdomain within the fibronectin-like repeats. *Journal of Investigative Dermatology*, **1999**, 112, 177-83	4.3	92
20	Alpha 2 beta 1 integrin mediates dermal fibroblast attachment to type VII collagen via a 158-amino-acid segment of the NC1 domain. *Experimental Cell Research*, **1999**, 249, 231-9	4.2	27
19	Epitope spreading: lessons from autoimmune skin diseases. *Journal of Investigative Dermatology*, **1998**, 110, 103-9	4.3	249
18	Interactions of the amino-terminal noncollagenous (NC1) domain of type VII collagen with extracellular matrix components. A potential role in epidermal-dermal adherence in human skin. *Journal of Biological Chemistry*, **1997**, 272, 14516-22	5.4	143
17	Development of an ELISA for rapid detection of anti-type VII collagen autoantibodies in epidermolysis bullosa acquisita. *Journal of Investigative Dermatology*, **1997**, 108, 68-72	4.3	107

16	Ultraviolet A irradiation upregulates type VII collagen expression in human dermal fibroblasts. *Journal of Investigative Dermatology*, **1997**, 108, 125-8	4.3	34
15	Colchicine for epidermolysis bullosa acquisita. *Journal of the American Academy of Dermatology*, **1996**, 34, 781-4	4.5	85
14	Type VII collagen specifically binds fibronectin via a unique subdomain within the collagenous triple helix. *Journal of Investigative Dermatology*, **1994**, 103, 637-41	4.3	29
13	Epidermal growth factor (EGF) promotes human keratinocyte locomotion on collagen by increasing the alpha 2 integrin subunit. *Experimental Cell Research*, **1993**, 209, 216-23	4.2	146
12	Labeling of fractured human skin with antibodies to BM 600/nicein, epiligrin, kalinin and other matrix components. *Journal of Dermatological Science*, **1993**, 5, 97-103	4.3	11
11	Identification and partial characterization of a novel 105-kDalton lower lamina lucida autoantigen associated with a novel immune-mediated subepidermal blistering disease. *Journal of Investigative Dermatology*, **1993**, 101, 262-7	4.3	69
10	Immunofluorescence on Salt-Split Skin for the Diagnosis of Epidermolysis Bullosa Acquisita. *Archives of Dermatology*, **1990**, 126, 229		24
9	Laminin inhibits human keratinocyte migration. *Journal of Cellular Physiology*, **1988**, 136, 140-6	7	147
8	Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated. *Journal of Investigative Dermatology*, **1988**, 91, 228-32	4.3	125
7	Clearing of epidermolysis bullosa acquisita with cyclosporine. *Journal of the American Academy of Dermatology*, **1988**, 19, 937-42	4.5	89
6	Organ-specific, phylogenetic, and ontogenetic distribution of the epidermolysis bullosa acquisita antigen. *Journal of Investigative Dermatology*, **1986**, 86, 376-9	4.3	37
5	Epidermolysis bullosa acquisita antigen, a major cutaneous basement membrane component, is synthesized by human dermal fibroblasts and other cutaneous tissues. *Journal of Investigative Dermatology*, **1986**, 87, 227-31	4.3	27
4	Evidence that anti-basement membrane zone antibodies in bullous eruption of systemic lupus erythematosus recognize epidermolysis bullosa acquisita autoantigen. *Journal of Investigative Dermatology*, **1985**, 84, 472-6	4.3	135
3	Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. *New England Journal of Medicine*, **1984**, 310, 1007-13	59.2	447
2	Epidermolysis bullosa acquisita--a pemphigoid-like disease. *Journal of the American Academy of Dermatology*, **1984**, 11, 820-32	4.5	220
1	Localization of basement membrane components after dermal-epidermal junction separation. *Journal of Investigative Dermatology*, **1983**, 81, 149-53	4.3	161